Aethlon Medical Statistics
Total Valuation
Aethlon Medical has a market cap or net worth of $7.78 million. The enterprise value is $1.47 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aethlon Medical has 1.61 million shares outstanding. The number of shares has increased by 837.95% in one year.
| Current Share Class | 711,136 |
| Shares Outstanding | 1.61M |
| Shares Change (YoY) | +837.95% |
| Shares Change (QoQ) | +161.90% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 9.79% |
| Float | 314,240 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.37 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -573.73 |
Financial Efficiency
Return on equity (ROE) is -136.76% and return on invested capital (ROIC) is -82.37%.
| Return on Equity (ROE) | -136.76% |
| Return on Assets (ROA) | -70.33% |
| Return on Invested Capital (ROIC) | -82.37% |
| Return on Capital Employed (ROCE) | -136.23% |
| Weighted Average Cost of Capital (WACC) | 10.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$896,437 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.95% in the last 52 weeks. The beta is 1.23, so Aethlon Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -76.95% |
| 50-Day Moving Average | 5.39 |
| 200-Day Moving Average | 7.21 |
| Relative Strength Index (RSI) | 40.23 |
| Average Volume (20 Days) | 32,350 |
Short Selling Information
The latest short interest is 43,186, so 2.69% of the outstanding shares have been sold short.
| Short Interest | 43,186 |
| Short Previous Month | 32,925 |
| Short % of Shares Out | 2.69% |
| Short % of Float | 13.74% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.25M |
| Pretax Income | -8.07M |
| Net Income | -8.07M |
| EBITDA | -7.93M |
| EBIT | -8.25M |
| Earnings Per Share (EPS) | -$17.80 |
Full Income Statement Balance Sheet
The company has $6.49 million in cash and $172,116 in debt, with a net cash position of $6.31 million or $3.93 per share.
| Cash & Cash Equivalents | 6.49M |
| Total Debt | 172,116 |
| Net Cash | 6.31M |
| Net Cash Per Share | $3.93 |
| Equity (Book Value) | 6.05M |
| Book Value Per Share | 3.77 |
| Working Capital | 5.58M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$7.26 million and capital expenditures -$15,019, giving a free cash flow of -$7.27 million.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | -15,019 |
| Depreciation & Amortization | 314,160 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.27M |
| FCF Per Share | -$4.52 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aethlon Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -837.95% |
| Shareholder Yield | -837.95% |
| Earnings Yield | -367.83% |
| FCF Yield | -88.54% |
Analyst Forecast
The average price target for Aethlon Medical is $13.25, which is 173.76% higher than the current price. The consensus rating is "Hold".
| Price Target | $13.25 |
| Price Target Difference | 173.76% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 4, 2026. It was a reverse split with a ratio of 1:5.
| Last Split Date | Aug 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |